BCR and leukemia: Here by searching for novel genotoxic drugs, we identified Bisindolylmaleimide IX, which was shown to be a DNA topoisomerase inhibitor, as a drug candidate against BCR-ABL or T315I BCR-ABL positive cells and cancer (solid or leukemia), while it was less effective in other cell types tested.